Influenza vaccine - Metaclipse Therapeutics
Latest Information Update: 21 Oct 2024
Price :
$50 *
At a glance
- Originator Metaclipse Therapeutics
- Class Cytokines; Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 21 Oct 2024 Preclinical development in Influenzas virus infections is ongoing in USA (Metaclipse Therapeutics pipeline, October 2024)
- 21 Oct 2024 Metaclipse Therapeutics plans a phase I trial for Influenza virus infections (prevention) in 2025 (Metaclipse Therapeutics pipeline, October 2024)
- 28 May 2022 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA